Up-regulation of CC chemokine ligand 20 and its receptor CCR6 in the lesional skin of early systemic sclerosis

European Journal of Dermatology

Volumn 21, Issue 5, 2011, Pages 731-736

  Tao, Juan ^a   Li, Lin ^b   Tan, Zhijian ^a   Li, Yan ^a   Yang, Jing ^a   Tian, Fen ^a   Wang, Li ^a   Ren, Yali ^a   Xu, Guangfen ^a   He, Xiaoliang ^a   Shen, Guanxin ^a   Tu, Yating ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CHENGDU SECOND PEOPLE S HOSPITAL   (China)

Author keywords

CCL20; Chemokine; Sclerosis; Systemic

Indexed keywords

CC CHEMOKINE LIGAND 20; CHEMOKINE; CHEMOKINE RECEPTOR CCR6; INTERLEUKIN 1BETA; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MONONUCLEAR CELL; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; UPREGULATION;

CELLS, CULTURED; CHEMOKINE CCL20; CHEMOTAXIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROBLASTS; HUMANS; INTERLEUKINS; MALE; RECEPTORS, CCR6; SCLERODERMA, SYSTEMIC; SKIN; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 80054908419     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1469     Document Type: Article

References (34)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009: 360: 1989-2003.
2. Gu YS, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008; 38: 132-60.
3. Yamamoto T. Scleroderma-pathophysiology. Eur J Dermatol 2009; 19: 14-24.
4. Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E, Sakkas L. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005; 64: 1233-5.
5. Homey B, Dieu-Nosjean MC, Wiesenborn A, et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000; 164: 6621-32.
6. Pastore S, Mascia F, Mariotti F, Dattilo C, Girolomoni G. Chemokine networks in inflammatory skin diseases. Eur J Dermatol 2004; 14: 203-8.
7. Atamas SP, White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 2003; 15: 772-7.
8. Distler JH, Akhmetshina A, Schett G, Distler O., Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009; 48: 98-103.
9. Yamamoto T. Chemokines and chemokine receptors in scleroderma. Int Arch Allergy Immunol 2006; 140: 345-56.
10. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003; 14: 409-26.
11. Chabaud M, Page G, Miossec P. Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 2001; 167: 6015-20.
12. Wu YY, Tsai HF, Lin WC, et al. Upregulation of CCL20 and recruitment of CCR6+ gastric infiltrating lymphocytes in Helicobacter pylori gastritis. Infect Immun 2007; 75: 4357-4363.
13. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-1576.
14. Carulli MT, Ong VH, Ponticos M, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005; 52: 3772-8372.
15. Vincent AS, Phan TT, Mukhopadhyay A, Lim HY, Halliwell B, Wong KP. Human skin keloid fibroblasts display bioenergetics of cancer cells. J Invest Dermatol 2008; 128: 702-9.
16. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 1993; 61: 239-246.
17. Atamas S P, White B. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 2003; 14: 537-5350.
18. Kawaguchi Y, McCarthy SA, Watkins SC, Wright TM. Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts. J Rheumatol 2004; 31: 1946-54.
19. Sakkas LI, Tourtellotte C, Berney S, Myers AR, Platsoucas CD. Increased levels of alternatively spliced interleukin 4 (IL- 4delta2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis. Clin Diagn Lab Immunol 1999; 6: 660-4.
20. Le Y, Zhou Y, Iribarren P, Wang J. Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol 2004; 1: 95-104.
21. Lisignoli G, Piacentini A, Cristino S, et al. CCL20 chemokine induces both osteoblast proliferation and osteoclast differentiation: Increased levels of CCL20 are expressed in subchondral bone tissue of rheumatoid arthritis patients. J Cell Physiol 2007; 210: 798-806.
22. Bohgaki T, Amasaki Y, Nishimura N, et al. Up regulated expression of tumour necrosis factor {alpha} converting enzyme in peripheral monocytes of patients with early systemic sclerosis. Ann Rheum Dis 2005; 64: 1165-73.
23. Schmuth M, Neyer S, Rainer C, et al. Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired\ permeability barrier function. Exp Dermatol 2002; 11: 135-42.
24. Kawashiri SY, Kawakami A, Iwamoto N, et al. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs. J Rheumatol 2009; 36: 2397-402.
25. Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T. Increase of CCL20 expression by human gingival fibroblasts upon stimulation with cytokines and bacterial endotoxin. Clin Exp Immunol 2005; 142: 285-91.
26. Miossec P, Briolay J, Dechanet J, Wijdenes J, Martinez-Valdez H, Banchereau J. Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis. Arthritis Rheum 1992; 35: 874-883.
27. de Waal Malefyt R, Figdor CG, Huijbens R, et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 1993; 151: 6370-81.
28. Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994; 179: 1517-27.
29. Huaux F, Liu T, McGarry B, Ullenbruch M, Phan S H. Dual roles of IL-4 in lung injury and fibrosis. J Immunol 2003; 170: 2083-92.
30. Serpier H, Gillery P, Salmon-Ehr V, et al. Antagonistic effects of interferon-gamma and interleukin-4 on fibroblast cultures. J Invest Dermatol 1997; 109: 158-62.
31. McGaha T, Saito S, Phelps R G, et al. Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Invest Dermatol 2001; 116: 136-43.
32. Kodera T, McGaha TL, Phelps R, Paul WE, Bona CA. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts. Proc Natl Acad Sci USA 2002; 99: 3800-3805.
33. Ong C, Wong C, Roberts CR, Teh HS, Jirik FR. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998; 28: 2619-29.
34. Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009; 129: 2175-83.